Pentylenetetrazol Induced Seizure (PTZ)
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Epilepsy is a significant medical problem facing millions of people, most of who are not controlled by the current anticonvulsants on the market. Although several marketed anticonvulsants exist there remains a significant unmet medical need for better anticonvulsants with reduced liability.
Pentylenetetrazole (PTZ), a GABA receptor antagonist, is used to create a common chemically- induced seizure model. Amongst all animal models of seizure and epilepsy, the pentylenetetrazole-induced seizures are categorized as a model of generalized seizure (versus partial or focal seizure). It produces a myoclonic seizure that models absence (petit mal) seizures. As a generalized seizure model it has features that differentiate it from the MES Seizure model (also a model of generalized seizure).
When screening anticonvulsant candidates the PTZ model is an excellent tool for evaluating anti-seizure characteristics compared to a focal or partial seizure model (Psychomotor Seizure) such as the 6 Hz Model. Compounds that enhance GABAergic transmission are effective in ameliorating seizure activity in the PTZ epilepsy model
The PTZ Seizure model can be conducted in either rats or mice. Most studies can be completed as a one-day procedure. Group sizes are generally 8-12 animals.